To help you understand and share this information, you can request our free booklet that summarizes the detailed information in the following sections. (This booklet was produced in February 2016, before the approval of several targeted therapies and immunotherapy drugs. Information about these drugs can be found in this section as well as in the Targeted Therapies and Immunotherapy sections of this website.)
Lung adenocarcinoma accounts for about 40% of all lung cancers. In addition to existing treatment approaches, promising new treatment approaches are being developed.
This website can help you:
- Learn what lung adenocarcinoma is
- Understand the treatment options available for lung adenocarcinoma
- Understand how to manage the side effects associated with lung adenocarcinoma treatment
- Consider whether participating in a clinical trial might be right for you
What is lung adenocarcinoma?
Lung adenocarcinoma is a subtype of A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. Lung adenocarcinoma is categorized as such by how the cancer cells look under a microscope. Lung adenocarcinoma starts in glandular cells, which secrete substances such as mucus, and tends to develop in smaller airways, such as alveoli. Lung adenocarcinoma is usually located more along the outer edges of the lungs. Lung adenocarcinoma tends to grow more slowly than other lung cancers.1,2,3,4
Lung adenocarcinoma accounts for 40% of all lung cancers. It is found more often in women. Younger people (aged 20-46) who have lung cancer are more likely to have lung adenocarcinoma than other lung cancers. Most lung cancers in people who have never smoked are adenocarcinomas.1,5
For more information about the signs and symptoms that might indicate lung adenocacinoma, see the Signs & Symptoms section. Note that lung adenocarcinoma may not cause any symptoms, especially early on in its development, and that the signs and symptoms are not specific to lung adenocarcinoma and may be caused by other conditions.
Diagnosing lung adenocarcinoma
Diagnosing lung cancer is a complex process. In addition to determining whether a patient has lung cancer, diagnosing includes categorizing lung cancers in ways that help to determine the best treatment plan.
How Is Lung Adenocarcinoma Diagnosed?
Different tests are used to diagnose lung cancer and determine whether it has spread to other parts of the body. Some of these tests can also help to decide which treatments might work best. Steps and tests used in diagnosing lung adenocarcinoma include:
- Imaging tests
- Laboratory tests
- Biopsies (A tissue biopsy is the only way to confirm a diagnosis of lung cancer.)
The diagnostic approaches used for an individual will depend on medical history and condition, symptoms, location of the nodule(s), and other test results.
For more information about the different steps and tests for making a lung cancer diagnosis, see the Diagnosing Lung Cancer section.
Stages of Lung Cancer
Staging is a way of describing where the cancer is located, if or where it has spread, and whether it is affecting other parts of the body. Doctors use diagnostic tests to determine the cancer’s stage, so staging may not be complete until all of the tests are finished. Knowing the stage helps the doctor to recommend a treatment plan. Lung cancer is treatable at all stages.
The staging system used for lung adenocarcinoma is the TNM system, where the combination of the values assigned to a patient's cancer on three measures—T (tumor), N (node), and M (metastasis)—determine the cancer's stage.Stages range from 0 to IV. The higher the stage number, the more advanced the cancer. Only stage IV is metastatic.6,7
The Lung Cancer Staging section provides more information about how stages are determined and the characteristics of each stage.
Biomarkers are features of a cancer that predict how it will respond to certain treatments. They are helpful in the determination of the most appropriate treatment for the cancer.
Biomarkers currently used in determining treatments for lung adenocarcinoma are:
- Driver mutations within the cancer DNA
- Levels of the PD-L1 protein
A patient's lung adenocarcinoma may have one of the many known driver mutations—changes in the patient's DNA that lead to lung adenocarcinoma or cause it to progress. In biomarker testing (also called mutation, genomic, or molecular testing), the patient's DNA is analyzed to determine whether any of these driver mutations is present. Five of these driver mutations have FDA-approved therapies that specifically target them. Per National Comprehensive Cancer Network (NCCN) guidelines, it is recommended that all patients with advanced-stage NSCLC have a type of biomarker testing called comprehensive biomarker testing. Patients should discuss biomarker testing with their doctor.38
Below are the driver mutations that have been identified for lung adenocarcinoma at this time:8
PD-L1 is a protein biomarker used to determine whether a lung adenocarcinoma patient is likely to benefit from treatment with one of the immuotherapy drugs—pembrolizumab (Keytruda®)—that is FDA-approved for lung adenocarcinoma patients.38
Treatment options for lung adenocarcinoma
There are a number of treatment options for lung adenocarcinoma. Which ones are used to treat a specific patient's lung cancer will depend on the stage of the cancer, the patient's overall health, including how well the organs of the patient's body are functioning, and the patient's preferences. A patient's age alone does not predict whether a patient will benefit from a treatment.5,7
Patients may be as involved in the treatment plan decision as they want to be. Patients should discuss all of the options, understand what the goal of each option is (for example, cure vs. control), consider the benefits and risks of each, check about likely side effects, understand how everyday life might be affected, find out what the treatment will mean financially, and not hesitate to get a second opinion if there are unaddressed concerns.36,37
It is always a good idea for a patient to take someone along to appointments to help with questions and take notes.
What Are Currently Approved Treatment Options?
Approved treatment options for lung adenocarcinoma include:
- Radiation therapy
- Targeted therapies
- Angiogenesis inhibitors
In addition, new treatments are being studied for lung adenocarcinoma. These are available through clinical trials.
For more information about approved treatment options for NSCLC by stage, see the Treatment Options for Non-Small Cell Lung Cancer by Stage section.
Surgery is a treatment option in lung cancer only when the patient is healthy enough for surgery, and the tumor:
- has been found early (is in one lung),
- is able to be completely removed safely, and
- has not spread within the chest or to other organs9,10
Surgery is the best chance for a cure. Among the types of surgery—lobectomy, wedge resection, segmentectony, pneumonectomy, and sleeve resection—lobectomy, the removal of an entire lobe, is currently considered to be the most effective.10,39
Read more about different surgical options, when they are used, and what to expect after surgery in the Treatment Options: Surgery section.
Radiation therapy is a type of cancer treatment that uses high-powered energy waves to kill cancer cells or reduce the size of tumors. It works by damaging the cancer cells' ability to multiply. Radiation only kills cancer cells directy in the path of the radiation.2,39
The type of radiation therapy most often used to treat non-small cell lung cancer, including lung adenocarcinoma, is external beam radiation therapy (EBRT), which is radiation directed at the lung cancer from outside the body. There are different types of EBRT that can be used, depending on the patient's situation.39
For more information about radiation treatment, including how it works, how and when it is given, the different kinds, and common side effects, see the Treatment Options: Radiation Therapy section.
Chemotherapy is a systemic drug treatment, most often given intravenously to lung cancer patients, that kills the rapidly growing cancer cells by traveling through the blood to reach the cancer cells wherever they are. Chemotherapy also kills rapidly growing healthy cells, which contributes to the side effects a patient may experience.
Patients whose lung cancer has spread beyond the lung to local lymph nodes are often given chemotherapy and radiation therapy. As with other types of non-small cell lung cancer, patients with lung adenocarcinoma are often given two chemotherapy agents as first-line therapy. Which drugs are chosen will depend in part on the patient’s overall health and ability to tolerate different possible side effects. For patients with lung adenocarcinoma, most often one of the platinum drugs cisplatin or carboplatin is combined with another chemotherapy drug, such as pemetrexed or doctataxel.10
For more information about chemotherapy, including how it works, how and when it is given, and possible side effects and how to manage them, see the Treatment Options: Chemotherapy section.
Targeted therapies are a type of therapy that targets cancer cells directly, rather than attacking all rapidly growing cells as chemotherapy does. Targeted therapies focus on specific parts of cells and the signals that cause cancer cells to grow uncontrollably and thrive.11 All of the targeted therapies that have been studied and approved by the US Food and Drug Administration (FDA) belong to a class of drugs called tyrosine kinase inhibitors (TKIs).
As discussed earlier, there are a number of known driver mutations in lung adenocarcinoma. TKIs are currently FDA-approved for patients with metastatic lung adenocarcinoma for five of them: the A gene that the body normally produces but, when it fuses with another gene produces an abnormal protein that leads to cancer cell growth gene rearrangement, the The protein found on the surface of some cells and to which epidermal growth factor binds, causing the cells to divide mutation, the ROS1 gene rearrangement, the BRAF V600E mutation, and the NTRK1 gene fusion. Lung cancers with these mutations are called ALK-positive, EGFR-positive, ROS1-positive, BRAF-positive, and NTRK1-positive, respectively.
ALK gene rearrangements occur in about 7% of patients with lung adenocarcinoma.8The following ALK inhibitors are currently FDA-approved for patients with ALK-positive metastatic non-small cell lung cancer, including lung adenocarcinoma:
- Alectinib (Alecensa®): as first-line and subsequent-line treatment12
- Brigatinib (Alunbrig®): for patients whose cancer has grown while they were on crizotinib or are intolerant to crizotinib13
- Ceritinib (Zykadia®): as first-line and subsequent-line treatment14
- Crizotinib (Xalkori®): as first-line and subsequent-line treatment15
- Lorlatinib (Lorbrena®): for patients whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as first-line therapy for metastatic disease16
EGFR mutations occur in about 15% of lung adenocarcinoma tumors.8There are currently five FDA-approved EGFR inhibitors approved for patients with metastatic EGFR-positive non-small cell lung cancer, including lung adenocarcinoma:
- Afatinib (Gilotrif®): as first-line treatmentfor patients whose tumors have non-resistant EGFR mutations17
- Dacomitinib (Vizimpro®): as first-line treatment for patients with EGFR exon 19 deletion or exon 21 L858R substitution mutations18
- Erlotinib (Tarceva®): for patients whose tumors have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations, for first-line treatment, Treatment that is given to help keep cancer from growing after it has shrunk or stabilized following initial therapy and for second-line or greater treatment after progression following at least one chemotherapy regimen.19
- Gefitinib (Iressa®): as first-line treatment for patients whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations20
- Osimertinib (Tagrisso®) as first-line treatment for patients with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations and for treatment for patients whose tumors are EGFR T790M-positive and whose disease has progressed on or after EGFR TKI therapy21
About 1% to 2% of patients with lung adenocarcinoma have tumors with a ROS1 mutation.8 There is currently one TKI that has been approved for patients with metastatic NSCLC whose tumors are ROS1-positive. This is crizotinib (Xalkori®), a TKI that is also used for patients with ALK-positive tumors.15
The BRAF V600E mutation is found in 1%-3% of lung adenocarcinoma patients.8 There is currently one FDA-approved combination inhibitor treatment for patients with metastatic NSCLC with the BRAF V600E mutation: dabrafenib (Tafinlar®) and trametinib (Mekinist®).22,23
The NTRK1 gene fusion is found in about 3% of lung adenocarcinoma patients.8 There is currently one FDA-approved TKI, larotrectinib (Vitrakvi®), for the treatment of patients whose solid tumors (e.g., lung, thyroid, colon):
- have an NTRK gene fusion (including the NTRK1 gene fusion among lung adenocarcinoma patients) without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or have progressed following treatment.24
The biggest challenge of TKIs is that patients with lung adenocarcinoma who initially benefit from them eventually develop resistance, known as Disease progression after initial benefit with a targeted therapy. Doctors and researchers are working to overcome resistance and to keep TKIs effective for longer periods of time.25
For more infomation about targeted therapies, including how they work, how and when they are given, possible side effects and how to manage them, and acquired resistance, see the Treatment Options: Targeted Therapy section.
As the body develops and grows, it makes new blood vessels to supply all of the cells with blood. This process is called angiogenesis. When the new blood vessels provide oxygen and nutrients to cancer cells, they help the cancer cells grow and spread.26
Angiogenesis inhibitors help stop or slow the growth or spread of tumors by stopping them from making new blood vessels. The tumors then die or stop growing because they cannot get the oxygen and nutrients they need. The way they do this is by blocking the cancer cells’ A protein made by cells that stimulates new blood vessel formation receptor.26
Currently, two angiogenesis inhibitors are FDA-approved for patients with non-small cell lung cancer, including lung adenocarcinoma:
- Bevacizumab (Avastin®): In combination with carboplatin and paclitaxel for the first-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic non-squamous NSCLC. Also for first-line treatment of patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic mutations in combination with atezolizumub (Tecentriq®), paclitaxel, and carboplatin 27, 31
- Ramucirumab (Cyramza®): In combination with docetaxel for the second-line treatment of patients with metastatic NSCLC whose disease has progessed on or after platinum-based chemotherapy. Patients with EGFR or ALK mutations should have disease progression on FDA-approved therapy for these mutations before receiving ramucirumab (Cyramza®).28
For more information about angiogenesis inhibitors, how they work, how and when they are given, and possible side effects and how to manage them, see the Treatment Options: Angiogenesis Inhibitors section.
Immunotherapy is a type of therapy that increases the natural ability of the patient's immune system to fight cancer. Instead of trying to stop or kill the patient's cancer cells directly, as most other cancer treatments do, immunotherapy trains the patient's own natural immune system to recognize cancer cells and selectively target and kill them.29,30
Currently, there are four FDA-approved immunotherapy drugs for patients with non-small cell lung cancer, including lung adenocarcinoma. These drugs belong to the type of immunotherapy called Agents that target the pathways tumor cells use to evade recognition and destruction by the immune system, which work by targeting and blocking the fail-safe mechanisms of the immune system. The goal is to block the immune system from limiting itself, so the immune system can target the cancer cells.30
The four FDA-approved immunotherapy drugs used to treat lung adenocarcinoma patients are:
- Atezolizumab (Tecentriq®):
- For first-line treatment of patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic mutations, in combination with bevacizumab, paclitaxel, and carboplatin
- For patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK mutations should have disease progression on FDA-approved therapy for those mutations before they are treated with atezolizumab (Tecentriq®)31
- Durvalumab (Imfinzi®): Approved for patients with stage III NSCLC whose tumors are not able to be surgically removed and whose cancer has not progressed after treatment with concurrent platinum-based chemotherapy and radiation therapy. (The purpose of this treatment is to reduce the risk of the lung cancer progressing.)32
- Nivolumab (Opdivo®): For patients with metastatic NSCLC whose cancer has progressed after platinum-based chemotherapy. Patients with EGFR or ALK mutations should have disease progression on FDA-approved therapy for those mutations before they are treated with nivolumab (Opdivo®)33
- Pembrolizumab (Keytruda®):
- In combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK mutations
- As a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 (Tumor Proportion Score [TPS] greater than or equal to 1%), as determined by an FDA-approved test, with no EGFR or ALK mutations, and is:
- stage III where patients are not candidates for surgical resection or definitive chemoradiation, or
- As a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS greather than or equal to 1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK mutations should have disease progression on FDA-approved therapy for those mutations before receiving pembrolizumab (Keytruda®)34
For more information about immunotherapy, including how the immune system works, possible side effects, other kinds of immunotherapy being studied, and questions to ask your healthcare team, see the Treatment Options: Immunotherapy section.
Finding a clinical trial that might be right for you
Clinical trials are research studies among patients to find out whether new medical approaches that are being developed are safe and effective and better than those currently being used.
In addition to the approved treatments described above, there is a great deal of promising research going on now in clinical trials focused on people with lung adenocarcinoma, including targeted therapies, immunotherapy. and new approaches in chemotherapy and radiation therapy.35 Clinical trials are an important option for patients thinking about lung adenocarcinoma treatments.
Patients considering participating in a clinical trial should start by asking their healthcare team whether there is one that might be a good match for them in their geographic area.
For more information about clinical trials and resources for finding one, see the Clinical Trials section.
Managing symptoms and side effects
Lung cancer treatments can cause side effects. Side effects from lung cancer treatment are common, but just because a side effect is common does not mean that a patient will experience it. Before treatment begins for lung adenocarcinoma, patients should discuss with their healthcare team what side effects might be expected and how to prevent or ease them. Patients should also speak with their healthcare team if and when new side effects begin, as treating them early on is often more effective than trying to treat them once they have already become severe. Although most side effects go away when treatment is over, some can last a long time.
In addition to the side effects of lung cancer treatment, lung cancer itself can result in a number of symptoms. For more information about the symptoms of lung cancer, see the Signs & Symptoms section.
Tips for managing specific symptoms and side effects related to treatment can be found in the For Supporters & Advocates section of the website, along with other practical and supportive resources for patients/survivors and caregivers.
To help reduce the severity and duration of most side effects and alleviate the cancer’s symptoms, a patient may want to request palliative care, also called “supportive care” or “symptom management.” There is sometimes confusion about the difference between palliative care and hospice care. Hospice care is a form of palliative care given only to patients whose life expectancy is six months or less. On the other hand, palliative care in general is an extra layer of support that can be initiated alongside other standard medical care. In fact, scientific evidence is starting to emerge that shows that palliative care may actually help patients live longer.
For more information about how palliative care can improve quality of life from the time of diagnosis, see the Palliative Care section.
The healthcare team
There are a number of doctors and other medical professionals who diagnose and treat people with lung cancer. Together, they make up the comprehensive medical or healthcare team that a patient sees over the course of their care. Members of the healthcare team work together to provide care for a patient, including diagnosis, treatment, and side-effect managment and other support services.
For more information about what each member of a healthcare team does, see the Your Medical Team section.
Updated June 13, 2019
- What is Non-Small Cell Lung Cancer? American Cancer Society website. https://www.cancer.org/cancer/non-small-cell-lung-cancer/about/what-is-non-small-cell-lung-cancer.html. Revised May 16, 2016. Accessed June 10, 2019.
- NCI Dictionary of Cancer Terms. National Cancer Institute website. http://www.cancer.gov/dictionary. Accessed June 10, 2019.
- Non-Small Cell Lung Cancer Treatment (PDQ®)—Patient Version. National Cancer Institute website. https://www.cancer.gov/types/lung/patient/non-small-cell-lung-treatment-pdq. Updated May 31, 2019. Accessed June 7, 2019.
- Chen Z, Fillmore M, et al. Non-small cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Aug; 14(8): 535-546. doi: 10.1038/nrc3775. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5712844/. Accesed June 10, 2019.
- deGroot PM, Wu CC, et al. The epidemiology of lung cancer. Trans Lung Cancer Res. 2018 Jun; 7(3): 220233. doi: 10.21037//tlcr.2018.05.06. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037963/. Accessed June 10, 2019.
- Lung Cancer: Metastatic—Non-Small Cell Lung Cancer. NCCN Guidelines for Patients. Version 3.2019. https://www.nccn.org/patient/guidelines/lung-metastatic. Posted January 18, 2019. Accessed June 11, 2019.
- Lung Cancer – Non-Small Cell: Stages. Cancer.Net website. http://www.cancer.net/cancer-types/lung-cancer-non-small-cell/stages. Approved January 20, 2019. Accessed June 11, 2019.
- Hirsch FR, Suda K, Wiens J, Bunn PA, Jr. New and emerging targeted treatments in advanced non-small-cell-lung-cancer. Lancet. Sep 3 2016. 388(10048): 1012-1024. Accessed June 11, 2019.
- Lung Cancer: Early and Locally Advanced—Non-Small Cell Lung Cancer. NCCN Guidelines for Patients. Version 3.2019. https://www.nccn.org/patients/guidelines/lung-early-stage. Posted January 18, 2019. Accessed June 11, 2019.
- Non-Small Cell Lung Cancer. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Version 4.2019. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Posted April 29, 2019. Accessed June 11, 2019.
- Understanding Targeted Therapy. Cancer.Net website. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/personalized-and-targeted-therapies/understanding-targeted-therapy. Approved January 2019. Accessed June 12, 2019.
- Alecensa® (alectinib) capsules [package insert].2017. Genentech, Inc., South San Francisco, CA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208434s003lbl.pdf. Revised November 2017. Accessed June 12, 2019.
- AlunbrigTM (brigatinib) tablets [package insert]. ARIAD Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceuticals Company, Cambridge, MA. http:www.accessdata.fda.gov/drugsatfda_docs/label/2017/208772lbl.pdf. Revised April 2017. Accessed June 12, 2019.
- Zykadia® (ceritinib) capsules [package insert]. 2014. Novartis, Basel, Switzerland. http://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/zykadia.pdf. Revised March 2019. Accessed June 12, 2019.
- Xalkori® (crizotinib) capsules [package insert]. 2011. Pfizer, Inc., New York, NY. http://labeling.pfizer.com/showlabeling.aspx?id=676. Revised January 2019. Accessed June 12, 2019.
- Lorbrena® (lorlatanib) tablets [package insert). 2018. Pfizer, Inc., New York, NY. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210868s000lbl.pdf. Revised November 2018. Accessed November 5, 2018.
- Gilotrif® (afatinib) tablets [package insert]. 2013. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf. Revised January 2018. Accessed June 12, 2019.
- Vizimpro® (dacomitinib) tablets [package insert]. 2018. Pfizer Inc., New York, NY. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211288s000lbl.pdf. Revised September 2018. Accessed June 12, 2019.
- Tarceva® (erlotinib) tablets [package insert]. 2014. OSI Pharmaceuticals, LLC., Northbrook, IL. https://www.gene.com/download/pdf/tarceva_prescribing.pdf. Revised October 2016. Accessed June 2019.
- Iressa® (gefitinib) tablets [package insert]. 2015. AstraZeneca Pharmaceuticals LP, Wilmington, DE. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206995s003lbl.pdf. Revised August 2018. Accessed June 12, 2019.
- Tagrisso® (osimertinib) tablets [package insert]. 2015. AstraZeneca Pharmaceuticals LP, Wilmington, DE. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf. Revised April 2018. Accessed June 12, 2019.
- Tafinlar® (dabrafenib) capsules [package insert]. 2013. Novartis Pharmaceuticals Corporation, East Hanover, NJ. https://www.hcp.novartis.com/globalassets/eg-plus-assets7/taf-mek/hcp/nsclc/global/tafinlar.pdf?id=39912. Revised May 2018. Accessed June 12, 2019.
- Mekinist® (trametinib) tablets [package insert]. 2013. Novartis Pharmaceuticals Corporation, East Hanover, NJ. https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/mekinist.pdf. Revised May 2018. Accessed June 12, 2019.
- Vitrakvi® (larotrectinib) capsules [package insert]. 2018. Loxo Oncology, Inc., Stamford, CT. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211710s000lbl.pdf. Revised November 2018. Accessed June 12, 2019.
- Lovly, C. Combating acquired resistance to tyrosine kinase inhibitors in lung cancer. Am Soc Clin Oncol Educ Book. 2016 FEb 1. doi: 10.14694/EdBook_AM.2015.35.e165. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4734636/. Accessed June 12, 2019.
- Angiogenesis Inhibitors. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/angiogenesis-inhibitors-fact-sheet. Reviewed April 2, 2018. Accessed June 12, 2019.
- Avastin® (bevacizumab) solution [package insert]. 2004. Genentech, Inc., South San Francisco, CA. https://www.gene.com/download/pdf/avastin_prescribing.pdf. Revised February 2019. Accessed June 12, 2019.
- Cyramza® (ramucirumab) injection [package insert]. 2014. Eli Lilly and Company, Indianapolis, IN. http://pi.lilly.com/us/cyramza-pi.pdf. Revised May 2019. Accessed June 12, 2019.
- Biological Therapies for Cancer. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/bio-therapies-fact-sheet. Reviewed April 26, 2018. Accessed June 12, 2019.
- Immunotherapy to Treat Cancer. National Cancer Institute website. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy. Updated November 18, 2018. Accessed June 12, 2019.
- Tecentriq® (atezolizumab) injection [package insert]. 2016. Genentech, Inc., South San Francisco, CA. https://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Revised May 2019. Accessed June 13, 2019.
- Imfinzi® (durvalumab) injection [package insert]. 2017. AstraZeneca Pharmaceuticals LP, Wilmington, DE. February 2018. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761069s002lbl.pdf. Revised February 2018. Accessed June 13, 2019.
- Opdivo® (nivolumab) injection [package insert]. 2014.Bristol-Myers Squibb Company, Princeton, NJ. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Revised May 2019. Accessed June 13, 2019.
- Keytruda® (pembrolizumab) injection [package insert]. 2014. Merck & Co., Inc., Whitehouse Station, NJ. https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Revised June 2019. Accessed June 13, 2019.
- Clinicaltrials.gov. US National Institutes of Health website. http://clinicaltrials.gov. Accessed June 13, 2019.
- Making Decisions about Cancer Treatment. Cancer.Net website. https://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Approved April 2018. Accessed June 13, 2019.
- Cancer treatment decisions: 5 steps to help you decide. Mayo Clinic website. https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/cancer-treatment/art-20047350. Updated April 25, 2019. Accessed June 13, 2019.
- Basu Roy, U. Comprehensive Biomarker Testing in Advanced-Stage Lung Cancers. Interview with Dr. Zosia Piotrowska. https://lungevity.org/experts-blog/webinar-comprehensive-biomarker-testing-in-advanced-stage-lung-cancers. Posted February 13, 2019. Accessed June 13, 2019.
- Lung Cancer - Non-Small Cell: Type of Treatment. Cancer.Net website. https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/types-treatment. Approved January 2019. Accessed June 19, 2019.